On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan. The first participant in MVCﾒs Phase 1 clinical trial was dosed with MVCﾒs COVID-19 vaccine combined with Dynavaxﾒs CpG 1018 adjuvant at National Taiwan University Hospital in early October.

The subsidy was released at agreed upon milestones in the total amount of up to NT$ 472 million (US$ 16.4 million). The grant received by MVC was earmarked by the Taiwan government for purposes of research and development of a locally produced COVID-19 vaccine.